Biotinylated Cynomolgus VEGF-D Protein, His,Avitag™

사용자 리뷰
제품 번호/규격
가격
Availability
수량
VED-C82E3-25ug
$350.00
In Stock - Delivery in 2 weeks
VED-C82E3-200ug (100ug X 2)
$1380.00
In Stock - Delivery in 2 weeks
총 항목 수 제품 금액$ 0

제품 세부정보

  • Synonyms

    FIGF, VEGFD

  • Source

    Biotinylated Cynomolgus VEGF-D Protein, His,Avitag (VED-C82E3) is expressed from human 293 cells (HEK293). It contains AA Phe 93 - Ser 201 (Accession # G7Q297).

    Predicted N-terminus: Phe 93

    Request for sequence
  • Molecular Characterization

    VEGF-D Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 19.7 kDa. The protein migrates as 28-33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    Biotin-labeled

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the SABA assay / HABA assay / binding ELISA.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • SDS-PAGE

    VEGF-D SDS-PAGE

    Biotinylated Cynomolgus VEGF-D Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     VEGF-D ELISA

    Immobilized Biotinylated Cynomolgus VEGF-D Protein, His,Avitag (Cat. No. VED-C82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) with a linear range of 0.001-0.313 μg/mL (QC tested).

    Protocol
  • Bioactivity-CELL BASE

     VEGF-D CELL

    Human VEGF-D Protein, His Tag (MALS verified), (Cat. No. VED-H52H3) induced VEGFR2 (Luc) reporter activity in HEK293 Cells. The EC50 for this effect is 1.450 μg/ml (Routinely tested).

    Protocol

사용자 리뷰
댓글 남기기

배경 소개

Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Vascular endothelial growth factor D

  • 카테고리:

  • 상장 의약품 수:

    0 상세

  • 임상 의약품 수:

    2 상세

  • 최고 개발 단계:

    Phase 2 Clinical

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호